Skip to main content
Fig. 1 | Thrombosis Journal

Fig. 1

From: Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study)

Fig. 1

The overall schema of the trial and the schedule of blood sampling. A Trial design and intervention of this study. B The blood sampling schedule. Time point 1: Ctrough day1 (first day of chemotherapy before administrating edoxaban), time point 2: Cmax day1 (first day of chemotherapy two hours after administrating edoxaban), time point 3: Ctrough day2 (day after chemotherapy initiation before administrating edoxaban), time point 4: Cmax day2 (day after chemotherapy initiation two hours after administrating edoxaban), time point 5: Ctrough day2* (day after the final chemotherapy session before administrating edoxaban), time point 6: Cmax day2* (day after the final chemotherapy session two hours after administrating edoxaban)

Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us